In this podcast, Dr Salim Benkhalifa, Medical Affairs Lead, Celltrion Healthcare France reflects on biosimilars development.
List view / Grid view
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
New data shows the non-inferiority of efficacy for the subcutaneous (SC) formulation of CT-P13 to the intravenous (IV) formulation of CT-P13 in people with rheumatoid arthritis.
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
23 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union.
20 February 2017 | By Niamh Marriott, Digital Editor
Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.
5 July 2016 | By Victoria White, Digital Content Producer
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
6 April 2016 | By Victoria White, Digital Content Producer
With this approval, Celltrion's Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US...
28 October 2015 | By Victoria White
New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patients with inflammatory bowel disease are switched to biosimilar infliximab Remsima from originator infliximab...
10 June 2015 | By Victoria White
Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis...
Experts share real-world experience with biosimilar infliximab in patients with inflammatory bowel disease
19 May 2015 | By Victoria White
Clinical experience of biosimilar infliximab shows that the treatment is comparable to the reference medicinal product in terms of efficacy and safety...